Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:BTMD NASDAQ:ELEV NASDAQ:ICCC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$4.02+2.2%$4.66$3.35▼$17.94$87.61M4.5228,524 shs77,163 shsBTMDbiote$2.27+0.2%$2.12$1.27▼$4.75$85.12M1.66223,422 shs160,219 shsELEVElevation Oncology$0.37$0.37$0.27▼$0.40$21.62M1.481.34 million shsN/AICCCImmuCell$9.82+3.5%$8.97$4.52▼$10.75$88.47M0.5522,728 shs44,758 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+1.00%-13.24%-3.22%-64.61%BTMDbiote0.00%-8.13%+13.57%+41.25%-42.93%ELEVElevation Oncology0.00%0.00%0.00%0.00%-4.20%ICCCImmuCell0.00%-1.96%-6.23%+48.05%+24.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$4.02+2.2%$4.66$3.35▼$17.94$87.61M4.5228,524 shs77,163 shsBTMDbiote$2.27+0.2%$2.12$1.27▼$4.75$85.12M1.66223,422 shs160,219 shsELEVElevation Oncology$0.37$0.37$0.27▼$0.40$21.62M1.481.34 million shsN/AICCCImmuCell$9.82+3.5%$8.97$4.52▼$10.75$88.47M0.5522,728 shs44,758 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+1.00%-13.24%-3.22%-64.61%BTMDbiote0.00%-8.13%+13.57%+41.25%-42.93%ELEVElevation Oncology0.00%0.00%0.00%0.00%-4.20%ICCCImmuCell0.00%-1.96%-6.23%+48.05%+24.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70390.66% UpsideBTMDbiote 2.50Moderate Buy$2.7521.41% UpsideELEVElevation Oncology 0.00N/AN/AN/AICCCImmuCell 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ELEV, AARD, ICCC, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/28/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.004/6/2026ICCCImmuCell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/ABTMDbiote$192.22M0.44$0.58 per share3.89($1.40) per share-1.62ELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AICCCImmuCell$29.93M2.97$0.20 per share49.22$2.99 per share3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/ABTMDbiote$27.05M$0.445.154.27N/A8.29%-25.72%15.12%8/5/2026 (Estimated)ELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%N/AICCCImmuCell-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%8/13/2026 (Estimated)Latest ELEV, AARD, ICCC, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ICCCImmuCell$0.05$0.21+$0.16$0.21$5.40 million$10.36 million5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 million3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06BTMDbioteN/A1.290.58ELEVElevation Oncology0.6719.4019.40ICCCImmuCell0.244.822.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ABTMDbiote21.68%ELEVElevation Oncology83.70%ICCCImmuCell13.47%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ABTMDbiote32.40%ELEVElevation Oncology8.10%ICCCImmuCell5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/ABTMDbiote19437.58 million25.41 millionNot OptionableELEVElevation Oncology4059.22 million54.43 millionOptionableICCCImmuCell709.05 million8.53 millionNot OptionableELEV, AARD, ICCC, and BTMD HeadlinesRecent News About These CompaniesICCC's Valuation Remains Premium: Is it Worth Overpaying for?June 18, 2026 | zacks.comImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong DemandMay 25, 2026 | zacks.comImmuCell (ICCC) Q1 2026 Earnings TranscriptMay 17, 2026 | aol.comAImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic GrowthMay 17, 2026 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comImmuCell Corporation (ICCC) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026May 14, 2026 | globenewswire.comHere’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap OpportunityMay 13, 2026 | insidermonkey.comImmuCell Reaches Settlement Agreement with Norbrook LaboratoriesMay 8, 2026 | tipranks.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026May 7, 2026 | globenewswire.comThe Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCellApril 22, 2026 | zacks.comWhy ImmuCell Corporation’s (ICCC) Stock Is Up 7.88%April 14, 2026 | aaii.comAImmuCell Corporation: ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board ...April 14, 2026 | finanznachrichten.deImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent DirectorsApril 13, 2026 | globenewswire.comImmuCell Corporation: ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsApril 9, 2026 | finanznachrichten.deImmuCell CorporationApril 9, 2026 | edition.cnn.comStocks to watch after market on Wednesday: ICCC, COST, STZApril 8, 2026 | seekingalpha.comImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsApril 8, 2026 | globenewswire.comImmucell Strengthens Board With New Director AppointmentMarch 18, 2026 | tipranks.comImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to BoardMarch 18, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Stocks Built to Thrive in a Higher-for-Longer EconomyBy Chris Markoch | June 15, 2026Fox Captures The Living Room With $22B Roku BuyBy Jeffrey Neal Johnson | June 17, 2026The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&ABy Jeffrey Neal Johnson | June 19, 2026ELEV, AARD, ICCC, and BTMD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$4.01 +0.09 (+2.16%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.biote NASDAQ:BTMD$2.26 +0.01 (+0.22%) As of 03:41 PM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Elevation Oncology NASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.ImmuCell NASDAQ:ICCC$9.82 +0.33 (+3.47%) As of 03:41 PM Eastern This is a fair market value price provided by Massive. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
